Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade
Clinical trial NCT02605642 · COMPLETED
Trial details
- NCT number
- NCT02605642
- Sponsor
- Pfizer
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2015-09-10
- Primary completion
- 2018-12-31
- Enrollment
- 351
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.